1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Medical - Pharmaceuticals
Infinity Pharmaceuticals, Inc.

Infinity Pharmaceuticals, Inc.

INFIQ
Infinity Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
9,076.00Market Cap
Infinity Pharmaceuticals, Inc.
INFIQ
(Other OTC)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
TTM
FRC
1.26
4.12
1.94
2.71
3.49
1.49
- -
3.4
2.22
0.38
0.12
0.4
0.05
0.03
0.02
0.03
0.03
Revenue per Share
-0.87
1.17
-1.19
-1.86
-1.5
-1.7
-2.64
-0.36
-2.62
-0.61
-0.83
-0.2
-0.83
-0.68
-0.53
-0.5
-0.46
Basic EPS, GAAP
0.5
-0.58
-0.28
-1.08
-1.3
-2.57
-2.41
2.4
-1.84
-3.12
-0.73
-0.09
-0.77
-0.6
-0.47
-0.48
-0.43
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-8.84
-7.36
-6.87
-8.7
-10.11
-10.18
-9.38
-9.62
-12.13
-12.61
-13.2
-12.25
-12.74
-12.8
-9.48
-9.59
-9.79
Book Value per Share
2.62
5.94
3.45
1.88
0.58
9.78
4.2
4.31
2.01
1.66
0.94
0.95
0.14
-0.38
0.25
-0.21
-0.42
Tangible Book Value per Share
20
20
26
26
27
32
48
49
49
50
51
55
57
60
86
89
90
Basic Weighted Avg Shares
25
83
51
71
93
47
- -
165
109
19
6
22
3
2
2
3
3
Sales/Revenue/Turnover
-94.92
22.94
-91.69
-67.62
-41.53
-210.49
- -
-4.8
-116.54
-764.34
-607.42
-53.87
-1,497.67
-2,239.5
-2,426.43
-1,729.43
-1,636.67
Operating Margin (%)
3
2
2
2
2
2
2
2
2
3
2
- -
- -
- -
- -
- -
- -
Depreciation Expense
-17
24
-31
-49
-40
-54
-127
-17
-128
-30
-42
-11
-47
-40
-45
-44
-41
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
-68.87
28.35
-61.61
-68.67
-43.16
-114.54
- -
-10.56
-117.7
-160.77
-697.17
-50.81
-1,543.36
-2,355.56
-2,436.06
-1,711.11
-1,593.93
Profit Margin (%)
97
121
119
75
89
311
203
290
185
78
47
52
35
25
69
27
8
Working Capital
- -
- -
- -
- -
38
- -
- -
15
20
19
- -
- -
2
23
1
- -
- -
LT Debt
51
120
90
49
15
310
201
209
99
82
48
52
8
-23
22
-19
-37
Total Equity
- -
22.27
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
-14.75
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
89
89
91
Market Capitalization
50
14
19

Working Capital

FRC

•

in mil. unless spec.
Dec'22
Mar'23
Jun'23
Total Current Assets
40
28
20
Cash, Cash Equivalents & STI
38
26
18
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
14
11
12
Payables & Accruals
11
8
9
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-99.75%
-171.01%
-188.32%
Free Cash Flow
40.26%
148.56%
4.48%
Net Income, GAAP
88.91%
48.19%
-1.97%
Sales/Revenue/Turnover
- -
37.38%
39.56%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
1
- -
- -
2
2022
1
1
1
1
3
2023
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
-0.15
-0.13
-0.12
- -
-0.53
2022
-0.14
-0.13
-0.12
- -
-0.5
2023
-0.12
-0.11
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2021
- -
- -
- -
- -
- -
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
Similar Companies
Easywell Biomedicals, Inc. (1799.TWO)
Camurus AB (0RD1.L)
YAKUODO HOLDINGS Co., Ltd. (7679.T)
Stayble Therapeutics AB (publ) (STABL.ST)
Al-Dawaa Medical Services Company (4163.SR)
Sugi Holdings Co.,Ltd. (7649.T)
Business
Infinity Pharmaceuticals, Inc. (INFIQ) is a clinical-stage biopharmaceutical company focused on developing small-molecule drugs targeting oncology pathways, including PI3K inhibitors for immuno-oncology applications; eganelisib (IPI-549), a selective PI3K-gamma inhibitor designed to reprogram immunosuppressive macrophages in the tumor microenvironment for solid tumors such as triple-negative breast cancer, urothelial cancer, and renal cell carcinoma; duvelisib, a dual PI3K-delta/gamma inhibitor previously advanced for hematologic malignancies like chronic lymphocytic leukemia; and earlier candidates including IPI-3063 (PI3K-delta), IPI-443 (PI3K-delta/gamma), IPI-493 (HSP90B), and IPI-926 (Hedgehog pathway). The company, founded in 1995 and headquartered in Cambridge, Massachusetts, has conducted operations primarily in the United States with global clinical trials through partnerships; it previously collaborated with Bristol-Myers Squibb on MARIO trials combining eganelisib with Opdivo, Roche/Genentech on front-line combinations with Tecentriq and Avastin/Abraxane, Arcus Biosciences on adenosine receptor antagonist regimens, and PellePharm on patidegib licensing. In recent major changes, Infinity filed for Chapter 11 bankruptcy on September 29, 2023, following the termination of a proposed merger with MEI Pharma due to activist shareholder opposition, leading to significant workforce reductions of approximately 75-78%; the U.S. Bankruptcy Court approved asset sales, including certain assets to Deerfield Healthcare Innovations Fund III for $1 million in December 2023 and substantially all remaining assets to an undisclosed healthcare investment firm in February 2024, with a revised liquidation plan confirmed on March 7, 2024, to distribute proceeds to creditors amid $21 million in assets and $58.6 million in liabilities.